CAR-T and Immunotherapy
Richard Wang*
CAR-T technology has become a new wave, which revolutionized cancer therapy with breakthrough clinical benefits for certain indications and renewed hope for cure. The technology was developed based on the evolving understanding and exploration of molecular immunology and rigorous clinical trial, culminating in the market approval of the first-of-its-kind two products in the US in 2017. As a new live cell modality, there are still neumorous challenges and improvement opportunities regarding its manufacturing, quality control, clinical management and commercial operation. This article is meant to give a brief introduction of the technology on the scientific principle, research and development in the world and China status, and future perspectives, with the hope to encourage more innovative scientists and clinicians to be involved in the further development of the technology for safe, efficacious and affordable cell therapy products to benefit patients.
CN
EN